GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Short Interest

Verseon (LSE:VERS) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Verseon Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Verseon's Short Interest

For the Biotechnology subindustry, Verseon's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verseon's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verseon's Short Interest distribution charts can be found below:

* The bar in red indicates where Verseon's Short Interest falls into.


Verseon (LSE:VERS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Short Interest
Comparable Companies
ASX:NEU TSX:RVX WAR:SLV VKTX TSX:NEPT TSX:VBV ARQL XKRX:060590 ADMA XKRX:142760 TYME XPAR:TNG XBRU:MDXH SCPH KIN XKRX:196170 OCSE:ORPHA LSE:IMM BOM:531349 VTL
Traded in Other Exchanges
N/A
Address
47071 Bayside Parkway, Fremont, CA, USA, 94538
Website
http://www.verseon.com
Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.

Verseon (LSE:VERS) Headlines